Aim: We aimed to assess  the  usability  ef-fectiveness  of  IPSS  voiding  to  storage  sub-score  ratio  in  men  with  lower  urinary  tract  symptoms (LUTS)  who  were  treated  with  α-blockers.  
Material and Methods: A total of 356 men with LUTS were included in this study. The  voiding  symptom  score (IPSS-V), storage  symptom  score (IPSS-S), and  the  IPSS-V/S  ratio  was  calculated. Alpha-blocker therapy was given to patients with IPSS-V/S >1. The IPSS-T, IPSS-V, IPSS-S, QoL (quality of life) were measured at 1 month and 3 months after treatment. Results were assessed by the changes of QoL.
Results: IPSS-T and IPSS-V values were significantly higher in patients with IPSS-V ⁄ S > 1 than IPSS-V ⁄ S ≤1 (p<0,001). Patients with IPSS-V ⁄ S > 1 were older than IPSS-V ⁄ S ≤1 (p=0,034). The mean IPSS-T and IPSS-V decreased and the QoL improved significantly at third month (p=0,004, p=0,001, p<0,001, re-spectively). 
Conclusion: IPSS-V/S >1 is a useful tool to define bladder outlet-related LUTD and to pre-dict treatment outcomes in patients with lower urinary tract symptoms.   
Key Words: Lower  urinary  tract  symp-toms, IPSS-V, IPSS-S, Alpha-blocker therapy
                                        
                                        
                                     
                                    
                                        
                                            Abstract
                                        
                                        Aim: We aimed to assess  the  usability  ef-fectiveness  of  IPSS  voiding  to  storage  sub-score  ratio  in  men  with  lower  urinary  tract  symptoms (LUTS)  who  were  treated  with  α-blockers.  
Material and Methods: A total of 356 men with LUTS were included in this study. The  voiding  symptom  score (IPSS-V), storage  symptom  score (IPSS-S), and  the  IPSS-V/S  ratio  was  calculated. Alpha-blocker therapy was given to patients with IPSS-V/S >1. The IPSS-T, IPSS-V, IPSS-S, QoL (quality of life) were measured at 1 month and 3 months after treatment. Results were assessed by the changes of QoL.
Results: IPSS-T and IPSS-V values were significantly higher in patients with IPSS-V ⁄ S > 1 than IPSS-V ⁄ S ≤1 (p<0,001). Patients with IPSS-V ⁄ S > 1 were older than IPSS-V ⁄ S ≤1 (p=0,034). The mean IPSS-T and IPSS-V decreased and the QoL improved significantly at third month (p=0,004, p=0,001, p<0,001, re-spectively). 
Conclusion: IPSS-V/S >1 is a useful tool to define bladder outlet-related LUTD and to pre-dict treatment outcomes in patients with lower urinary tract symptoms.   
Key Words: Lower  urinary  tract  symp-toms, IPSS-V, IPSS-S, Alpha-blocker therapy